ATE382366T1 - Modifizierte myelin proteinmoleküle - Google Patents

Modifizierte myelin proteinmoleküle

Info

Publication number
ATE382366T1
ATE382366T1 AT96913035T AT96913035T ATE382366T1 AT E382366 T1 ATE382366 T1 AT E382366T1 AT 96913035 T AT96913035 T AT 96913035T AT 96913035 T AT96913035 T AT 96913035T AT E382366 T1 ATE382366 T1 AT E382366T1
Authority
AT
Austria
Prior art keywords
polypeptides
plp
useful
modified
mbp
Prior art date
Application number
AT96913035T
Other languages
English (en)
Inventor
John Mueller
Michael Lenardo
Henry Mcfarland
Louis Matis
Eileen Mueller
Steven Nye
Clara Pelfrey
Stephen Squinto
James Wilkins
Original Assignee
Alexion Pharma Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/431,644 external-priority patent/US7041503B2/en
Application filed by Alexion Pharma Inc, Us Health filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of ATE382366T1 publication Critical patent/ATE382366T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96913035T 1995-05-02 1996-04-22 Modifizierte myelin proteinmoleküle ATE382366T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43164895A 1995-05-02 1995-05-02
US08/431,644 US7041503B2 (en) 1995-05-02 1995-05-02 Modified myelin basic protein molecules
US48211495A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ATE382366T1 true ATE382366T1 (de) 2008-01-15

Family

ID=27411744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913035T ATE382366T1 (de) 1995-05-02 1996-04-22 Modifizierte myelin proteinmoleküle

Country Status (8)

Country Link
EP (1) EP0830139B1 (de)
JP (1) JPH11511650A (de)
KR (1) KR100682350B1 (de)
AT (1) ATE382366T1 (de)
AU (1) AU5565896A (de)
CA (1) CA2218858A1 (de)
DE (1) DE69637391T2 (de)
WO (1) WO1996034622A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US7041503B2 (en) 1995-05-02 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Modified myelin basic protein molecules
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6528699B1 (en) * 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
EP1522591A3 (de) * 1997-02-25 2005-08-17 GTC Biotherapeutics, Inc. Transgen produzierte nicht-sekretierte Proteine
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
CN1301752A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——plp蛋白10和编码这种多肽的多核苷酸
CN1301756A (zh) * 1999-12-29 2001-07-04 复旦大学 一种新的多肽——髓磷脂p0蛋白14和编码这种多肽的多核苷酸
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
ATE489400T1 (de) * 2002-09-06 2010-12-15 Genentech Inc Verfahren zur proteinextraktion
AU2003300932A1 (en) * 2002-12-16 2004-07-29 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
US20050272097A1 (en) * 2004-02-18 2005-12-08 Emanuel Calenoff Methods and compositions for detecting and treating autoimmune diseases
KR100791996B1 (ko) * 2006-08-02 2008-01-04 고려대학교 산학협력단 미엘린 염기성 폴리펩타이드를 분비하는 형질전환 미생물을함유하는 자가면역질환 치료용 조성물
US10759838B2 (en) 2015-03-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
US12458683B2 (en) 2015-03-09 2025-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen

Also Published As

Publication number Publication date
EP0830139A1 (de) 1998-03-25
DE69637391D1 (de) 2008-02-14
CA2218858A1 (en) 1996-11-07
KR100682350B1 (ko) 2008-11-06
KR19990008329A (ko) 1999-01-25
WO1996034622A1 (en) 1996-11-07
DE69637391T2 (de) 2008-08-14
EP0830139A4 (de) 2001-10-10
AU5565896A (en) 1996-11-21
EP0830139B1 (de) 2008-01-02
JPH11511650A (ja) 1999-10-12
MX9708418A (es) 1998-10-31

Similar Documents

Publication Publication Date Title
DE69637391D1 (de) Modifizierte myelin proteinmoleküle
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
NO982794D0 (no) Diagnostisering og behandling av AUR-1 og/eller AUR-2 relaterte lidelser
FR2751986B1 (fr) Gene implique dans le cadasil, methode de diagnostic et application therapeutique
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
DE60142693D1 (de) Arzneimittel für herzversagen
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP0957926A4 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DK1056452T3 (da) Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter
Ezzedine et al. Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity
ATE182180T1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
Fukuda et al. Barrier integrity and immunity: exploring the cutaneous front line in health and disease
DE69228997D1 (de) Menschliche il-3-varianten
DK100487A (da) Hidtil ukendte carbonsyrederivater, fremgangsmaade til deres fremstilling, deres anvendelse samt laegemidler indeholdende disse forbindelser
PT948604E (pt) Produtos e metodos relacionados com pyk2
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
Stern et al. Amelioration of proteolipid protein 139–151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
ATE485377T1 (de) Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties